Rearrangements of oncogenes c-myc and c-abl were detected by non-radioactive hybridisation in a case of Burkitt's lymphoma/leukaemia. The surface phenotype of Burkitt's cells were positive for CD19, CD20, HLA-DR, CD14, CD33 and surface immunoglobulin markers. Although cytogenetic analysis was not performed, the c-myc and heavy immunoglobulin genes had the same 14-2 kilobase EcoRI molecular size fragment, suggesting a possible t(8;14) translocation which is a common marker of this malignancy. The c-abl oncogene was also rearranged in DNA digested BamHI and EcoRI. The physiopathological implications of the rearranged c-abl gene are unknown, this being the first case, as for as is known, of Burkitt's lymphoma/ leukaemia with a rearranged c-abl gene. (7 Clin Pathol 1993;46:778-779) Some haematological malignancies represent the best human tumour models of well defined mutations in the development of carcinoma. The first example was the finding of the Philadelphia chromosome' in chronic myelogenous leukaemias (CML) due to a t(9; 22) translocation in which the c-abl oncogene (9q34) is juxtaposed into the bcr region (22q1 1).2 In Burkitt's lymphoma the c-myc oncogene (8q24) 
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Results
The Burkitt's lymphoma cells with a mixed B lymphoid-myeloid phenotype showed rearrangements of the c-myc and c-abl oncogenes. The probes detected the germline fragments generated by the restriction enzymes acting on normal DNA and additional rearranged fragments. The rearranged bands were weaker than the germline bands, as expected from the observation that malignant cells comprised only 14% of the cells studied. The c-myc probe detected rearranged fragments of 14-2 kilobase EcoRI and 6-2 kilobase PstI; the immunoglobulin heavy chain gene probe revealed two additional fragments of 14-2 and 9.5 kilobases (fig 1) . The similar fragment size (14-2 kilobases) suggests that due to the rearrangement the parts of the c-myc and HIg genes recognised by the probes might lie together in the same EcoRI fragment. The rearranged c-abl gene had 3-4 kilobase BamHI and 7 9 kilobase EcoRI molecular fragment sizes (fig 2) .
Discussion
We found c-myc and c-abl rearranged genes in a CD14 and CD33 positive Burkitt's B E c-abl lymphoma. The presence of more than one mutant oncogene in malignant cells is considered a sequential process, representing progression from low to high grade malignancy.5-9 Some oncogenes are rearranged in relatively common tumours such as a follicular lymphoma, with bcl-2 rearranged in a t(14;18), or such as chronic myelocytic leukaemia with c-abl rearranged in t(9;22), both considered to be low grade malignancies. The expansion of a malignant clone increases the probability of new mutations which would exacerbate the aggressiveness of the tumour. This fact has already been reported for some follicular lymphomas with a bcl-2 rearrangement which evolve into high grade lymphomas6 8 and for those CML progressions in chronic phase which evolve into an acute phase as a result of an amplification or rearrangement of the c-myc oncogene. 9 We detected a rearrangement of the c-myc gene in a restricted fragment of 14-2 kilobase EcoRI in Burkitt's lymphoma. It coincides with that observed in the rearrangement of the H-Ig gene, suggesting a possible t (8;14) translocation, a common marker of this malignancy. The physiopathological implications of a rearranged c-abl gene in this aggressive Burkitt's lymphoma/leukaemia and its possible role in the pathogenesis of this malignancy are unknown, although the results obtained by the authors suggest that this Burkitt's lymphoma/leukaemia evolved from a low grade malignancy. The highly aggressive nature of this malignancy which killed the patient, might be determined by the association of these two mutated oncogenes, or by the expression of a mixed lymphoid/ myeloid phenotype, as generally speaking, the haematological malignancies of a mixed phenotype indicate a worse prognosis and poorer survival.'0
